Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 plus donafenib in advanced hepatocellular carcinoma
CTR20240100Phase 2Active
- Sponsor
- Zelgen
- Start
- May 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig, donafenib in hepatocellular carcinoma (HCC), sponsored by Zelgen. Started May 2024; status: active.
02
Drugs
nilvanstomigdonafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20240100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240100.